Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 155,149 | 177,134 | 204,745 | 188,657 | 98,193 |
| Marketable Securities | 410,181 | 323,808 | 265,775 | 250,208 | 247,727 |
| Receivables | 110,363 | 110,393 | 100,079 | 102,350 | 94,532 |
| Inventories | 61,041 | 71,525 | 61,936 | 35,819 | 20,768 |
| TOTAL | $788,284 | $728,916 | $675,296 | $616,125 | $499,170 |
| Non-Current Assets | |||||
| PPE Net | 3,988 | 4,144 | 4,370 | 4,612 | 4,884 |
| Intangibles | 105,515 | 107,859 | 110,204 | 65,490 | 66,855 |
| Other Non-Current Assets | 79,081 | 73,180 | 65,233 | 62,729 | 61,631 |
| TOTAL | $188,584 | $185,183 | $179,807 | $132,831 | $133,370 |
| Total Assets | $976,868 | $914,099 | $855,103 | $748,956 | $632,540 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 19,081 | 19,882 | 19,332 | 17,543 | 12,310 |
| Accrued Expenses | 324,864 | 317,969 | 311,265 | 236,711 | 197,293 |
| TOTAL | $343,945 | $337,851 | $330,597 | $254,254 | $209,603 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 55,743 | 59,548 | 60,462 | 62,947 | 60,763 |
| TOTAL | $55,743 | $59,548 | $60,462 | $62,947 | $60,763 |
| Total Liabilities | $399,688 | $397,399 | $391,059 | $317,201 | $270,366 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 166,392 | 165,876 | 165,221 | 164,772 | 164,180 |
| Common Shares | 16 | 16 | 16 | 16 | 16 |
| Retained earnings | -2,348,128 | -2,380,893 | -2,414,282 | -2,430,837 | -2,476,634 |
| Other shareholders' equity | 858 | -339 | -229 | 24 | -319 |
| TOTAL | $577,180 | $516,700 | $464,044 | $431,755 | $362,174 |
| Total Liabilities And Equity | $976,868 | $914,099 | $855,103 | $748,956 | $632,540 |